ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR
ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR
-
Clinical Trial Information
Trial Contact: Marquart, Vashnie; Ngo, George M.; Cox, Caitlin L; Longstreet, Jamie H
Trial Phone: 321-843-1037 ; 3218439657 ; 321-841-1505 ; 321-842-9567
-
IRB No: W20.028.03
Protocol Abbrev: ACURATE IDE
Principal Investigator: Vijaykumar S Kasi, PhD
Phase: Device: Significant Risk
Age Group: Adult
Secondary Protocol No: S2408
Treatment: Transcatheter Aortic Valve Replacement (TAVR)
Therapies Involved: Procedural
ClinicalTrials.gov ID: NTC03735667
-
Objective
The ACURATE Transfemoral Aortic Valve System is intended to improve aortic valve function in subjects with severe native aortic stenosis who are indicated for TAVR.
-
Key Eligibility
• Demographics including age and gender
• Medical history (general medical; cardiac [including previous cardiac surgery]; neurological, renal [including creatinine] and peripheral disease; and other medical conditions)
• Physical examination including weight and height o NYHA classification
• Current antiplatelet and other cardiovascular medications o Planned use of BAV (i.e., predilation)
• Risk assessments: Society of Thoracic Surgeons (STS) score, euroSCORE II, heart team assessment including an in-person evaluation by a center cardiac surgeon and any frailty assessments (detailed in next bullet). In the United States, CMS currently requires independent evaluations by 2 cardiac surgeons for reimbursement.
